Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate use programme for use of MIS 416 in patients in New Zealand with secondary progressive multiple sclerosis.

Next Previous
Trial Profile

Compassionate use programme for use of MIS 416 in patients in New Zealand with secondary progressive multiple sclerosis.

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIS 416 (Primary)
  • Indications Multiple sclerosis
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 20 May 2015 Results published in an Innate ImmunoTherapeutics media release.
  • 17 Dec 2014 New trial record
  • 12 Dec 2014 Seven patients have recently been added to the compassionate use group, bringing the total number of such patients to 25, according to an Innate Immunotherapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top